Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3064)	1/3/2011 9:21:08 AM
From: Jibacoa	Respond to of 3722

ISPH is down 58.57% in pre-market trading.<g> bigcharts.marketwatch.com It announced today that the results from its second PIII, TIGER-2, with denufosol tetrasodium for the treatment of cystic fibrosis, didn't achieve statistical significance for its primary efficacy endpoint.<g> Patients receiving denufosol in the 466-patient, double-blind, placebo-controlled clinical trial had an improvement of only 40 mL in FEV1, compared to 32 mL for the patients receiving placebo (p=0.742). The CEO stated, “These TIGER-2 results were disappointing and unexpected given the treatment effect observed in the TIGER-1 trial." "We expect to provide a detailed corporate update by mid-February. Meanwhile, we will continue to focus on our ophthalmology business.” The ACTAY was $10 <g> If the stock can get back to the $6 level, it wouldn't be a bad gain from present levels around $3.50 <g> Will put ISPH on a watch list,as it still seems better to watch for further developments.<g> bigcharts.marketwatch.com Bernard